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Abstract
Lung cancer is the number one cancer killer in the United States. This disease is clinically divided
into two sub-types, small cell lung cancer, (10–15% of lung cancer cases), and non-small cell lung
cancer (NSCLC; 85–90% of cases). Early detection of NSCLC, which is the more common and less
aggressive of the two sub-types, has the highest potential for saving lives. As yet, no routine
screening method that enables early detection exists, and this is a key factor in the high mortality
rate of this disease. Imaging and cytology-based screening strategies have been employed for early
detection, and while some are sensitive, none have been demonstrated to reduce lung cancer
mortality. However, mortality might be reduced by developing specific molecular markers that can
complement imaging techniques. DNA methylation has emerged as a highly promising biomarker
and is being actively studied in multiple cancers. The analysis of DNA methylation-based
biomarkers is rapidly advancing, and a large number of potential biomarkers have been identified.
Here we present a detailed review of the literature, focusing on DNA methylation-based markers
developed using primary NSCLC tissue. Viable markers for clinical diagnosis must be detectable in
'remote media' such as blood, sputum, bronchoalveolar lavage, or even exhaled breath condensate.
We discuss progress on their detection in such media and the sensitivity and specificity of the
molecular marker panels identified to date. Lastly, we look to future advancements that will be
made possible with the interrogation of the epigenome.
Background
Worldwide lung cancer kills over one million people each
year, and as the leading cause of cancer death in men and
second leading cause in women, it is a major health prob-
lem [1]. This disease is largely smoking-associated. While
in developed countries smoking rates are decreasing, the
use of tobacco products is increasing in developing coun-
tries. In combination with a spike in the number of lung
cancer cases in never smokers, this ensures that lung can-
cer will remain a major health problem [1]. Clinically,
lung cancer is divided into two subtypes, small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC).
SCLC is the more aggressive subtype, and accounts for 10–
15% of all cases. The remaining 85–90% of cases are clas-
sified as NSCLC, which is further histologically subdi-
vided into four categories; adenocarcinoma (AD),
squamous cell carcinoma (SQ), large cell carcinoma (LC)
and 'others', for example cancers of neuroendocrine ori-
gin.
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In the United States lung cancer is the number one cancer
killer in both men and women, accounting for over
160,000 deaths each year [2]. Interestingly, it is not the
most commonly diagnosed cancer; breast and prostate
cancer have a higher incidence. A reason for this disparity
is that early detection methods exist for breast and pros-
tate cancer, and these are widely used in the population.
As a result, the five-year survival rate is 89 and 99%
(respectively) for these cancers, as opposed to a very low
15% for lung cancer [2]. When early stage lung cancer is
detected, the survival rate can increase dramatically. For
example, one report on detection of early stage cancers
using low dose spiral computed tomography (LDSCT)
described a ten-year survival rate of 88% [3]. While there
is concern that LDSCT leads to overdiagnosis (detection of
indolent cancers that would normally not lead to death),
it is undisputed that effective early detection of lesions
that would otherwise progress to invasive cancer could
reduce lung cancer mortality. In an effort to achieve early
detection many imaging and cytology-based strategies
have been employed, however none have yet been proven
effective. Molecular markers would provide an alternative
approach and among them, DNA methylation alterations
show great promise. Here we present an update of the
field of DNA methylation markers for early lung cancer
detection.
Early detection of lung cancer
Original early detection methods for lung cancer were
focused on screening using chest X-ray and sputum cytol-
ogy. Randomized controlled trials demonstrated no
reduction in mortality using these techniques [4,5]. The
question has been raised as to whether these trials had
enough statistical power to determine a mortality benefit
[5,6]. The Prostate, Lung, Colorectal and Ovarian cancer
trial currently being conducted by the National Cancer
Institute is a larger trial and may conclusively reveal
whether chest X-ray screening can reduce mortality [5]. As
discussed later, studies of molecular instead of cytological
changes in sputum samples appear promising [7].
Following the apparent failure of chest X-ray and sputum
cytology as effective screening techniques, attention was
focused on a more sensitive imaging method – Low Dose
Spiral Computed Tomography (LDSCT). Several trials of
LDSCT as a screening tool in high-risk populations have
been conducted [8-14]. It is clear that LDSCT is more sen-
sitive than chest X-ray [11,12], as it can detect non-calci-
fied nodules as small as 1 mm. Such high sensitivity
comes with a price. The number of non-calcified nodules
detected is far greater than the number of actual cancers.
A Mayo Clinic study in 1999 reported that <2.0% of non-
calcified nodules detected were actually cancer [15]. This
presents two potential problems for LDSCT as an early
detection method. Firstly, there is the potential for many
false positive results, which would result in low specificity
if LDSCT were applied as a lung cancer screening tool. The
second problem is that in order to determine which nod-
ules are actually cancer, patients will require follow up
procedures (further scans, possibly biopsies or resec-
tions). These are costly, invasive, and can result in patient
morbidity and mortality. Crestanello et al. report that 9
out of 54 patients underwent surgery for benign nodules
[16]. A review of seven studies by Diederich and Wor-
manns reported that 4–55% of patients had invasive pro-
cedures for benign lesions [6].
An increase in survival in LDSCT-screened lung cancer
patients has been reported; the IELCAP study reports an
88% 10-year survival [3]. Many argue that the increased
survival rate seen is due to an overdiagnosis bias. Using
the Yankelevitz criteria of overdiagnosis – a tumor volume
doubling time (VDT) of > 400 days [17] – 27% of the
detected cancers in a study by Lindell et al. would be con-
sidered overdiagnosed [8]. In a review by Jett of a Japanese
study, 33% of the cancers detected have a VDT of >400
days [18], and hence would be considered overdiagnosed
[15]. Using a predictive model, Bach and colleagues
recently examined the combined results of LDSCT screen-
ing trials from three centers. They found an excess number
of cases diagnosed at each screening point compared to
the predicted number, without a decline in the number of
advanced cancers being detected. This supports the notion
of overdiagnosis in LDSCT screening [19]. The true meas-
ure of efficacy of an early detection method is a reduction
in mortality. Whether LDSCT screening in high-risk pop-
ulations decreases lung cancer mortality remains
unknown. The answer to this question will hopefully be
provided by one of several ongoing randomized control-
led trials (for example the US-based National Lung
Screening Trial, and in the Netherlands, the Dutch Lung
Cancer Screening Trial). The conclusions from such trials
will determine the fate of LDSCT as an early detection
strategy.
Another imaging-based early detection approach is
autofluoresence bronchoscopy (AFB). This distinguishes
between tumor and non-tumor tissue based on the
tumor-specific change in tissue autofluoresence. AFB has
been shown to be effective at detecting preneoplastic
lesions and lung cancers [20]. The drawbacks of the
method are that it is invasive, it mainly detects centrally
located cancers [21], and it is not highly specific [21,22].
Since imaging techniques have not yet proven effective as
an early detection method, a sensitive and specific screen-
ing strategy remains to be found. To fill this void, research
focus has shifted to molecular approaches. The goal is to
identify molecular markers (generally DNA, RNA or pro-
tein) that reflect characteristics of lethal tumors, and thatMolecular Cancer 2008, 7:81 http://www.molecular-cancer.com/content/7/1/81
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can be exploited for early detection of these lesions at the
pre-invasive stage. To function as molecular markers in a
screening test, these molecules must be detectible in
remote media. If molecular markers that allow detection
of cancer are identified, they will require complementary
highly sensitive imaging methods such as LDSCT to locate
the cancer. Identified molecular markers could be poten-
tially targeted by agents to help specifically enhance
tumor imaging [23].
DNA methylation
One highly promising molecular biomarker is DNA meth-
ylation. This enzymatic addition of a methyl group at the
5-position of the cytosine in a CpG (cytosine-guanine)
dinucleotide is a normal process within cells. In cancer,
despite a global hypomethylation, one observes hyper-
methylation in regions of the genome described as CpG
islands [24,25]. These islands are present in almost half of
all genes and are frequently promoter-associated [26]. The
common occurrence of DNA hypermethylation in all
types of cancer makes it an ideal biomarker, one that has
been extensively investigated. An advantage of DNA
methylation over protein-based markers is that it is read-
ily amplifiable and easily detectable using PCR-based
approaches. In addition, contrary to cancer-specific muta-
tions, which could occur anywhere in a gene, cancer-spe-
cific DNA hypermethylation occurs in defined regions,
usually in or near the promoter of genes. Thus, it is easy to
devise targeted probes to measure this molecular altera-
tion. Conveniently, these probes can be readily combined
into panels, which is important because no single molec-
ular alteration involved in cancer can be expected to be
present in every cancer case. Thus DNA methylation at a
single gene would likely allow detection of a subset of
cancers. Assembly of a complementary panel of DNA
methylation probes would therefore increase sensitivity
[27,28]. Finally, it has been demonstrated that methylated
DNA can be isolated from 'remote media' making it well-
suited for non-invasive detection [29,30].
Overview of DNA methylation analysis in NSCLC
In this review, we focus on DNA methylation-based
biomarkers for early detection of NSCLC. Because NSCLC
is the less aggressive lung cancer subtype, and accounts for
85–90% of all cases, its early detection holds the most
promise for saving lives. A plethora of studies describing
DNA methylation in non-small-cell lung cancer exist.
These studies are summarized in three tables, which, due
to their size, are attached to this manuscript as Additional
files 1, 2, 3. Each file lists the relevant loci in alphabetical
order. Additional file 1 lists information from studies of
less than 20 loci. Additional file 2 lists the results of DNA
methylation studies of 20 or more loci, or genome wide
approaches. Lastly, Additional file 3 discusses loci studied
in remote media from cancer patients. The contents of
these tables are discussed in more detail below.
Initial DNA methylation studies in NSCLC focused on
single loci (or a small number of well known loci) that
were selected because of their potential functional role in
cancer. The goals of these studies were a) to see if methyl-
ation was involved in lung cancer pathogenesis, or b) to
determine if methylation of a given gene could be corre-
lated with clinical factors, and hence serve as a prognostic
marker. This led to the characterization of the DNA meth-
ylation status of many loci in NSCLC (listed in Additional
file 1) [31-103]. The information gathered in these studies
could be of clinical use for early detection, chemo preven-
tion, diagnosis, treatment or prognosis [104]. Further
studies employed panels of 8–19 loci (including these
previously reported loci) for DNA methylation profiling
[105-116] (see Additional file 1). This profiling was
aimed at characterizing methylation status of many loci in
NSCLC, or in some cases, at identifying loci with the high-
est methylation frequency in tumors versus non-tumor tis-
sues, that could potentially be used as DNA methylation-
based biomarkers of the disease.
Several loci identified in both types of studies (e.g. APC,
CADM1, CDH1, CDH13, CDKN2A/p14(ARF), CDKN2A/
p16, DAPK, FHIT, GSTP1, MGMT, MLH1 and RASSF1A)
are reported to be methylated multiple independent times
in the literature (reviewed in Additional file 1), and there
is general consistency in the observed methylation fre-
quency for these loci. Any inconsistencies could have mul-
tiple explanations, for example: the use of different
techniques to study the methylation status, differences in
the population in each study, and a difference in the sub-
type composition of the NSCLC collection studied.
To further characterize DNA methylation in NSCLC and
facilitate the discovery of new markers, more recent stud-
ies have employed approaches that analyze large numbers
of loci at one time. In these studies, the goal has been to
identify DNA methylation-based discriminators of tumor
and normal tissues, and tumor subtypes. Some of these
approaches were targeted; the loci analyzed were selected
based on their relationship to cancer. Other approaches
were not designed to interrogate DNA methylation at spe-
cific loci, instead they examined the genome in greater
depth and identified potentially informative DNA meth-
ylation biomarkers based on comparative profiling
between tumor and non-tumor cells/tissues. The most
promising loci to emerge from these reports are reviewed
in Additional file 2. One targeted approach is to use
sodium bisulfite-treated DNA (in which unmethylated Cs
have been converted to Us) for semi-quantitative real time
PCR (MethyLight) to examine methylation levels of mul-
tiple loci. Three recent reports described an examinationMolecular Cancer 2008, 7:81 http://www.molecular-cancer.com/content/7/1/81
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of 27 loci in NSCLC [117], 28 loci in AD [27], and 42 loci
in SQ [28] using MethyLight. All three studies described a
panel of loci with the ability to sensitively and specifically
detect cancer. Using a MALDI-TOF based approach 47 loci
were studied in tumor and non-tumor tissues from 96
patients. Six loci (CLEC3B (previously TNA), MGP,
RASSF1, SDK2, SERPINB5 and XAGE1A (previously
GAGED2)) with statistically significantly higher methyla-
tion in tumor samples compared with non-tumor samples
were identified [118]. A targeted microarray was used to
study the methylation status of 59 loci (245 CpGs) and a
set of loci to discriminate SQ (ADPRH (formerly ARH1),
GP1BB, RARB and TMEFF2) and AD (CDKN1C, MGMT,
TMEFF2) from normal lung was identified [119]. In a sim-
ilar system, the promoter regions of 288 cancer-related
genes were examined. Twenty-eight potential biomarker
loci were identified and 5 were further examined in lung
cancer tissues, yielding two (PAX3 and PYCARD/ASC)
that showed frequent hypermethylation [120]. Restriction
landmark genomic scanning (RLGS) allows interrogation
of up to 2000 promoter sequences. In a study of 1184
CpG islands Dai et al. discovered 11 genes that are differ-
entially methylated in cancer, two of which are methyl-
ated in ≥ 50% of tumors (GNAL and PDX1) [121]. A
newer high throughput approach is the Illumina Golden-
Gate platform, which examines 1505 CpG sites in 807
genes. Recently a panel of loci that detects adenocarci-
noma was discovered, of which 8 were further examined
by bisulfite genomic sequencing (ASCL2, CDH13,
HOXA11, HOXA5, NPY, RUNX3, TERT and TP73) [122].
A study using a large methylation microarray analyzed the
promoter regions of 8091 loci, identifying the frequently
methylated CIDEB gene [123].
While these approaches can be used to determine the
DNA methylation status of large numbers of genes, a non
locus-targeted approach that allows unbiased interroga-
tion of DNA methylation in the genome could examine
far more loci. This could yield additional biomarkers, as
well as new information about general DNA methylation
patterns in lung cancer. Using an expression microarray
one can identify genes induced in cell lines treated with a
DNA methylation inhibitor. Such genes are potential
DNA methylation targets. Using this approach, Shames et
al. identified 132 tumor-specific methylation candidates,
45 of which were further investigated, revealing seven
potential lung cancer markers (ALDH1A3, BNC1,
CCNA1, CTSZ, LOX, MSX1 and NRCAM) three of which
showed frequent tumor-specific hypermethylation com-
pared to non-tumors [124]. Cortese et al. used a different
approach, studying the DNA methylation of genes that are
differentially expressed in fetal vs. adult lung. Four loci
(FGFR3, LAPTM5, MDK, MEOX2) were identified as aber-
rantly methylated in lung cancer, one with high frequency
[125].
Using a methylated CpG island recovery assay coupled
with microarray analysis (MIRA-microarray), Rauch et al.
enriched for CpG regions and then hybridized this to a
CpG microarray containing 12,192 CpG islands, ≥ 60% of
which map to the 5' end of known or putative genes. Mul-
tiple highly methylated loci were identified, of which the
top 50 were reported [126]. In follow-up studies they
identified several loci as markers for SQ lung cancer [127],
including HOXA7 and HOXA9 [128]. It is of note that
while the non-targeted approaches have the potential to
rapidly identify many more biomarkers, the candidate
biomarker loci must still be validated in primary tumors
using traditional approaches.
In general, there is not a large overlap between the top loci
identified in the targeted and non-targeted approaches.
Several frequently methylated loci identified in early stud-
ies, for example CDKN2A/p16, CDH13, MGMT and
RASSF1 remain viable markers when assessed in a larger
context, providing support for their role in cancer devel-
opment/progression [27,28,118,119,122]. Methylation
of genes that are occupied by transcriptionally repressive
polycomb group protein in embryonic stem cells, such as
members of the HOX and PAX families, was detected by
targeted as well as genomic approaches. This reinforces
the notion that these genes may be prone to cancer-spe-
cific methylation [129]. Further investigation of this
group of genes is warranted.
Modest overlap between the top loci from the non-tar-
geted studies is seen. This might be expected as each of
these approaches differ in their methods of experimenta-
tion, data analysis and ranking of loci as biomarkers. It
also indicates that further markers remain to be identified
and that development of the optimal panel will require
additional studies. Ongoing genome-wide analyses using
a multitude of approaches will help solve this issue, but it
is important that these analyses be carried out on all his-
tological subtypes of lung cancer. As previously discussed,
NSCLC is comprised of four histological sub-groups. The
two most common subtypes, adenocarcinoma and squa-
mous cell lung cancer, are quite distinct in both physical
location and molecular profile [118,119,130-133]. They
show differential methylation profiles as reported by Field
et al. and Brena et al. [79,119]. Indeed work in our lab sup-
ports the notion of different methylation patterns in SQ
and AD [27,28]. The distinct nature of AD and SQ means
an optimal lung cancer methylation panel will probably
require markers for both subtypes. Markers for LC and
other minor NSCLC groups, such as neuroendocrine can-
cers, remain to be developed.
DNA methylation in remote media
While using primary tissue to study methylation status is
useful to discover potential biomarkers, this material isMolecular Cancer 2008, 7:81 http://www.molecular-cancer.com/content/7/1/81
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not non-invasively accessible and is therefore not useful
for screening an at-risk population. The ideal system for
early diagnosis is material collected in a non-invasive/
minimally invasive way that will contain methylated
DNA. For this, one looks to remote patient media – blood,
naturally produced or induced sputum, exhaled breath-
condensate (EBC, non-invasive), and bronchoalveolar
lavage (BAL, semi-invasive). Multiple studies show that
DNA methylation of certain loci can be detected in blood,
sputum and BAL (Additional file 3). A few show that
genetic alterations can be detected in EBC, as discussed
below, although no published studies of DNA methyla-
tion detection in this medium exist.
The ideal remote medium is blood – it can be applied to
all patients, both those at minimal and high risk, and is
minimally invasive to obtain. It is reported that cancer
patients have a higher level of circulating DNA than non-
cancer cases [134], and that genetic [135-137], and epige-
netic [138] alterations can be detected in said DNA. It is
postulated that this DNA is released due to necrotic cell
death [139]. Over 25 loci have been reported to be meth-
ylated in plasma/serum of NSCLC patients
[29,41,45,52,55,60,140-144] (reviewed in Additional file
3). Several studies examined methylation in primary
tumor material and corresponding plasma/serum, and in
these cases methylation in blood was only seen in patients
in which the primary tumor also exhibited methylation
[52,60,142]. Many of the most promising markers from
Additional file 1 and 2 have not yet been investigated in
blood.
There are, however, caveats to detection of DNA methyla-
tion in blood. It is questioned as to whether there is
enough methylated DNA in the blood to efficiently detect
tumors at an early enough stage for curative resection.
While DNA quantity may be low, ongoing research on
more sensitive detection methods may overcome this
issue. Another potential problem is that blood as a remote
medium is not organ-specific; loci that are methylated in
lung cancer may be methylated as well in other cancers,
for example TNFRSF10C and D [113] TCF21 [36], RUNX3
[89], APC [145], FBN2 [68]. Thus, methylation of these
loci in blood could point to cancer in any one of several
organs. The best markers for lung cancer would therefore
be ones that show methylation only in lung cancer. Given
the recent focus on more genome wide approaches to
study methylation in many cancer types, a comparison of
DNA methylation profiles across cancer sites should soon
be possible. An alternative to this is to complement DNA
methylation marker screening with sensitive imaging
techniques to identify the cancer site. Another option is to
examine remote media that are more lung-specific.
Sputum is produced by increased bronchial secretions,
and is commonly found in smokers, hence it can be used
to screen high-risk populations. (In former or non-smok-
ers, it is much more difficult to obtain, though it can be
induced.) The advantages of sputum as a screening tool
include its non-invasive procurement, and the fact that it
contains cells from the lungs and lower respiratory tract.
However, the material in sputum is from the center of the
lungs, and it may not be as useful for the detection of ade-
nocarcinoma, which generally occurs at the periphery.
DNA methylation, mutations, and microsatellite altera-
tions have been detected in sputum, indicating it is a use-
ful source of tumor material [7,29,146]. Reports of DNA
methylation in sputum are summarized in Additional file
3[29,57,59,77,80,97,113,140,147,148]. It has been dem-
onstrated that promoter methylation in sputum increases
with cancer risk [29], increases as the time to lung cancer
decreases [147], and in the case of CDKN2A/p16 and/or
MGMT, can be found in sputum up to 3 years before diag-
nosis of squamous cell lung cancer [149]. A study by Liu
et al. using 50 matched tumor, plasma and sputum sam-
ples showed that CDKN2A/p16 hypermethylation is
detected in 84% of tumors, and 76% of sputum samples
from the same patients, demonstrating that this remote
medium is potentially effective in detecting lung cancer
[55]. However, whether this detection is applicable to all
NSCLC subtypes remains to be determined.
Exhaled breath provides a source of materials that can
reflect the disease state of the lungs. Breath condensate,
comprised mostly of water vapors, also contains lipids,
proteins, DNA and oxidation products – the levels of
which may differ between healthy and diseased subjects
[150]. Several studies report the utility of EBC in detection
of asthma, chronic obstructive pulmonary disease
(COPD) and cystic fibrosis [150]. EBC has also been used
for NSCLC detection. Carpagnano et al. reported detection
of the mitogenic factor endothelin-1 (ET1-1) in EBC of
lung cancer patients. In a small study they showed a statis-
tically significant difference in ET-1 levels between
healthy controls and NSCLC patients, and between stage
I-III and stage IV patients [151]. They have shown similar
results when looking at interleukin-6 [152]. While these
studies are protein-based, they do demonstrate the prom-
ise of EBC for early detection of lung cancer. Thus far,
there are no published reports of DNA methylation detec-
tion in EBC, although two studies reported collecting suf-
ficient DNA quantities to perform PCR-based assays for
microsatellite alterations and p53 mutations [153,154].
Of concern is the fact that the p53 mutations detected in
EBC differ from those found in the primary tumor from
the same patient [153,154]. This raises concern regarding
the origin of DNA obtained from EBC (it may also come
from cells in the esophagus, throat or mouth) and its util-
ity as a remote medium.Molecular Cancer 2008, 7:81 http://www.molecular-cancer.com/content/7/1/81
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Bronchoalveolar lavage (BAL) is another potential screen-
ing material for early detection of lung cancer. While
obtaining lavage fluid is not as invasive as a biopsy, it
requires bronchoscopy. However, bronchoscopy is rou-
tinely performed in suspected lung cancer cases and lav-
age fluid can be easily obtained during this procedure. An
advantage of BAL is that it allows localized harvesting of
lung-specific material, so that the fluid can be expected to
contain lung cancer cells and/or DNA. Several investiga-
tions of DNA methylation in BAL have been conducted
[30,39,99,100,155-160] (Additional file 3). Results vary
between studies. De Fraipont showed low levels of DNA
methylation in BAL from tumor-bearing patients, indicat-
ing that this would not be a good medium for marker
detection [157]. In contrast, Topalogu used a panel of loci
and detected 68% of their tumor cases by examining DNA
methylation in the corresponding BAL from the same
patients [39]. Kim et al. also reported a good correlation
between methylation in tumors and BAL, ranging from
39–61% for the five loci they analyzed [30]. DNA methyl-
ation has also been detected in control BAL from non-
neoplastic patients [30,159,160]. The detection of DNA
methylation in cancer-free patients is cause for concern if
presence/absence of DNA methylation is being used as a
diagnostic measure of cancer. However, if a quantitative
assay to determine DNA methylation levels is applied,
then one can determine a cut-off value, above which a
sample would be considered positive, as was done by
Grote et al. [159] and Schmiemann et al. [160].
The analyses of DNA methylation markers in remote
media are still in their early stages, and although many
show low sensitivity, the inclusion of more of the recently
identified promising markers (Additional file 2) in future
studies would likely boost detection of cancer cases. Pub-
lished data so far supports the continued analysis of these
fluids in search of an early detection method that can, at
the very least, complement imaging-based screening of at
risk subjects.
Selection of DNA methylation-based biomarkers for early 
detection of NSCLC
While a plethora of loci are reported to serve as potential
DNA methylation-based biomarkers for NSCLC, the
important question is: Which should be chosen for fur-
ther evaluation, and eventually for screening of subjects?
When performing a screening test there are four potential
outcomes. The first two of these, true-positive results (TP,
those who test positive and actually have cancer), and
true-negative results (TN, those who test negative and do
not have cancer), are the desired outcome of a screening
test. However, false-negative results (FN, those who have
cancer but do not test positive), and false-positive results
(FP, those who do not have cancer but test positive),
could do serious harm to the screening populations. False
negative results have the ramification of delaying diagno-
sis of the disease, hence endangering patients' lives, while
false positive results significantly affect patient quality of
life [161]. Sensitivity, defined as TP/(TP+FN), and specifi-
city, defined as TN/(TN+FP), measure the balance of these
results in the population. These measures can serve as the
selection criteria to determine which potential biomarkers
are pursued further. An ideal DNA methylation-based
biomarker would be highly sensitive and specific in all
populations studied, regardless of age, gender, ethnicity,
risk factors and tumor stage. However, given the differ-
ences between NSCLC subtypes and smoking and non-
smoking associated NSCLC, markers that function accu-
rately in a subset of the population could also be of use.
The likelihood of identifying a single marker with 100%
sensitivity and specificity is negligible.
The methylation frequency for many loci examined in
early studies is quite low in primary tumors (Additional
file 1, for example, DAPK 16–47%, p16 23–81%, CDH13
28–48%, and RASSF1A 15–54%). If the methylation fre-
quency is low, sensitivity will suffer as the locus yields too
few cases. Even for the more frequently methylated loci
listed in Additional file 2, one DNA methylation marker
cannot be expected to detect all cases of a particular can-
cer. The way to address this problem is to study the DNA
methylation status of multiple loci (a panel) in a sample
population. To ensure high sensitivity individual loci in
the panel should be highly penetrant, i.e. have a high fre-
quency in the population, and be complementary, i.e.
detect different tumor cases.
While ensuring high sensitivity is important, given very
sensitive imaging approaches like LDSCT, the more criti-
cal issue in lung cancer screening is high specificity. False-
positive results precipitate not only patient anxiety, but
also follow up procedures that are invasive, costly, and
have associated morbidity and mortality. The incidence
for lung cancer in the United States is 79.4/100,000 in
men and 52.6/100,000 in women [162]. This shows that
less than 0.1% of the population will get lung cancer.
Hence, a population-based screening using any marker
with a specificity of less that 99.9% will detect more false
positive cases than true positive ones. Such a marker
therefore cannot function as a screening marker in the
population at large. However, in current smokers the risk
of lung cancer is greatly increased (incidence of over 230
per 100,000 for both men and women [163]), and the
specificity of a marker can be slightly lower when screen-
ing is targeted to this high-risk group.
Sensitivity and specificity have been reported for several
locus panels when examining methylation in DNA iso-
lated from primary tissue. The area under the curve (AUC)
of a receiver operating characteristic (ROC) curve is aMolecular Cancer 2008, 7:81 http://www.molecular-cancer.com/content/7/1/81
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measure of the ability of a continuous marker to accu-
rately classify tumor and non-tumor tissue. Such a curve is
a plot of sensitivity vs 1 minus specificity values associated
with all dichotomous markers that can be formed by var-
ying the value threshold used to designate a marker "pos-
itive". An AUC of 1 corresponds to a marker with perfect
accuracy, while an AUC of 0.5 corresponds to an unin-
formative marker. Shivapurkar et al. studied the DNA
methylation of 11 loci to distinguish between NSCLC and
adjacent non-tumor lung tissue. Using a logistic regres-
sion with a binary outcome indicator of tumor and non-
tumor lung tissue, and a marker panel as covariates, they
demonstrated that a combination of HS3ST2 (3OST2),
DAPK and TNFRSF10C (DcR1) gave an ROC curve with
an AUC of 0.959 when comparing tumor and adjacent
non-tumor lung tissue. This implies that this combination
of markers could sensitively and specifically detect lung
cancer [113]. Ehrich et al. studied the methylation of 47
loci and developed a panel of 6 that could distinguish can-
cer from adjacent normal tissue with >95% sensitivity and
specificity [118]. Feng et al. developed a panel of 8 loci, of
which the presence of methylation of one gene was found
in 80% of NSCLC tissues [117]. In an effort to develop
markers for specific NSCLC subtypes, Tsou et al. reported
a panel of 4 loci with 94% sensitivity and 90% specificity
for AD [27], while Anglim et al. reported a panel of 4 loci
that with 96.5% sensitivity and 93.3% specificity for SQ
lung cancer [28]. Both reports compare DNA methylation
in tumor and adjacent non-tumor tissue from the same
patients. On a larger scale, Bibikova et al. identified 55 loci
that distinguished AD from adjacent non-tumor lung with
100% sensitivity and 92% specificity [122]. These are all
encouraging results, implying that DNA methylation
detection could serve as a viable early detection biomar-
ker, but these loci must be further validated in larger,
racially/ethnicially and gender balanced independent
populations in order to ensure equal functionality for all
patients. Also, primary tissue would not be the source
material tested in screening for early detection, hence,
promising loci must be interrogated for their potential to
sensitively and specifically detect cancer in remote media.
There are multiple reports of DNA methylation in blood,
but not all assess the sensitivity and specificity of the loci.
In those that do, it appears that detection in blood is com-
monly not sensitive [140,143]. For example, sensitivity
ranged from 7–27% for CDH13, CDKN2A/p16, DAPK,
GATA5, MGMT, PAX5α, PAX5β and RASSF1A in serum,
but is much higher in sputum for the same samples [140].
One way in which investigators have tried to increase sen-
sitivity is by defining a patient positive if a minimum
number of loci are methylated. For example, Fujiwara et
al. also described a low sensitivity of 49.5% when looking
at methylation of at least one of 5 loci in serum
(CDKN2A/p16, DAPK, MGMT, RARB and RASSF1A) but
specificity was 85% [143]. Recently a report examining
the methylation of CDH13, CDKN2A/p16, FHIT, RARB,
RASSF1A and ZMYND10 (BLU) in which methylation of
any 2 loci in plasma was considered cancer positive
showed 73% sensitivity and 82% specificity [45]. This
reinforces the notion that a panel of complementary loci
is necessary. In an interesting report, Bearzatto et al.
showed that combining CDKN2A methylation with mic-
rosatellite alterations in plasma increased sensitivity to
62%, and using CDKN2A methylation combined with cir-
culating DNA levels increased specificity to 80%, as
opposed to examining CDKN2A methylation alone [164].
While neither of these is ideal as a clinical test, it is of note
that the marker panels need not consist solely of DNA
methylation-based markers.
Many studies indicate that sputum could be a promising
remote medium for early detection. Shivapurkar et al.
described a combination of 4 loci, APC, CDKN2A/p16,
HS3ST2 (3OST2), and RASSF1A that serve as a good panel
for early detection of NSCLC in sputum, with an AUC of
0.8 [113]. Similarly, Li et al. reported a combination of
FHIT and HYAL2 with 76% sensitivity and 85% specificity
[7]. Wang et al. described MLH1 methylation in sputum
to have 60% sensitivity and 86% specificity [77], and
Belinsky showed that concomitant methylation of three
or more of a panel of 6 loci resulted in 64% sensitivity and
specificity [147]. In contrast, Cirincione et al. reported
that 3 loci, CDKN2A/p16, RARβ2 and RASSF1A are of lim-
ited use in early detection of lung cancer using sputum as
a remote medium [59].
Detection of DNA methylation in bronchoalveolar lavage
is also documented. Grote et al. published two reports,
using either APC or RASSF1A alone for NSCLC detection.
In both cases there is low sensitivity (30 and 34% respec-
tively) but high specificity (98.5 and 100% respectively)
[156,158]. Using just CDKN2A/p16, Xie et al. describe a
higher sensitivity (64%) than any other reports on DNA
methylation in BAL when examining a single locus and a
modest specificity (75%) [165]. Grote et al. explored the
use of marker combinations in two studies. In the first
they used CDKN2A/p16 and RARB2 in combination and
showed 69% sensitivity and 87% specificity in their pop-
ulation [159]. In another study they applied a marker
panel (APC, CDKN2A/p16, and RASSF1) to detect cancer
in 247 patients, and reported 53% sensitivity and, in cases
without a previous history of cancer, >99% specificity
[160]. It is probable that the inclusion of more highly
penetrant markers in such panels would increase sensitiv-
ity. This again highlights the need for a panel of markers,
and underlines the need to combine molecular markers
with imaging techniques.Molecular Cancer 2008, 7:81 http://www.molecular-cancer.com/content/7/1/81
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Conclusion
Lung cancer is responsible for a million cancer deaths per
year worldwide, and its detrimental effects will continue
to increase. Research focused on biomarker-based early
detection has the potential to reduce mortality rates. What
will it take to obtain functional DNA methylation markers
for early lung cancer detection?
Sullivan-Pepe outlined the five phases of biomarker dis-
covery[166]. The first phase, clinical exploratory, consists
of identification of promising markers. Much work on
identification of DNA-methylation based markers has
already been done, as described in Additional files 1 and
2, and a number of markers has been carried forward to
phase two, the clinical detection of established disease
(Additional file 3). However, with the advent of new tech-
niques, a thorough evaluation of the epigenome of all
types of cancer will soon be possible. The pool of poten-
tial DNA methylation markers for lung cancer has by no
means been exhausted, and it is expected that additional
high penetrance markers will be identified. It will be
important to examine DNA methylation in each of the
major lung cancer histological subtypes and ensure the
functionality of identified markers in lung cancers from
both genders and all races/ethnic groups. In addition,
given the fact that half of all new lung cancer cases arise in
ex-smokers or never smokers [167], and the observed
molecular differences between lung cancer from smokers
and non-smokers [168], it would be important to ensure
representation of lung cancer from never smokers in these
marker screens. Standardization of epigenomic assay tech-
niques and data analysis would facilitate comparisons of
DNA methylation profiles between cancer types, which
may allow the identification of true lung-cancer specific
hypermethylation. Ideally, only reproducibly hypermeth-
ylated high penetrance DNA methylation markers should
be carried forward to the analysis of systematically col-
lected remote media (because remote media are such a
valuable resource). The most promising markers can then
be tested in retrospective longitudinal studies (phase
three), in which materials collected prior to disease onset
are examined. Studies of DNA methylation in sputum and
BAL collected prior to diagnosis already look promising
(e.g. [149,160]), and results can improve further with the
inclusion of new high sensitivity/specificity marker pan-
els. If results are promising, prospective screening studies
(phase four) should follow to determine the extent and
properties of detected disease and measure the false refer-
ral rate. Lastly, case control studies should be done to
measure any effect on lung cancer mortality.
If a strong DNA methylation marker panel were devel-
oped, the manner in which it would be applied would
depend on its sensitivity and specificity. It is unlikely that
DNA methylation markers, or any molecular markers for
that matter, would be used on their own. Instead, we envi-
sion that they will be applied in concert with high-resolu-
tion imaging. In the near future, the prospect of genome-
wide interrogation of DNA methylation in lung cancer is
extremely exciting. The resulting information may provide
not only new candidate markers for early detection, but
also for monitoring response to therapy and recurrence. In
addition, methylation information could be linked to
pathobiology and clinical characteristics, potentially pro-
viding indicators for treatment and prognosis. Much work
remains to be done, but using epigenomics while building
on the experience and materials obtained from prior stud-
ies, we are well armed to make non-invasive testing for
early lung cancer detection a reality.
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